BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  GlaxoSmithKline  Biologicals  S.A.  submitted  on  2  December  2004  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Rotarix,  through  the 
centralised  procedure.  The  eligibility  to  the  centralised  procedure  was  agreed  upon  by  the 
EMEA/CHMP on 19 November 2004. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
P. Neels 
Co-Rapporteur:  E. Skovlund 
Licensing status: 
Rotarix has been given a Marketing Authorisation in Mexico on 12 July 2004. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 2 December 2004.  
The procedure started on 20 December 2004. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
2 March 2005.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 1 March 2005. 
The BWP during its meeting of 11-13 April 2005 adopted the BWP Report to be transmitted to 
the CHMP for endorsement. 
During the meeting on 18-21 April, the CHMP agreed on the consolidated List of Questions to 
be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  
21 April 2005. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
9 August 2005. 
The summary report of the inspection carried out at the manufacturing site Rixensart on 1 June 
2005 was issued on 8 August 2005.  
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  22 September 2005. 
During  the  CHMP  meeting  on  13  October  2005,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
The  applicant  submitted  the  responses  to  the  CHMP  list  of  outstanding  issues  on 
4 November 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of outstanding issues to all CHMP members on  25 November 2005. 
During  the  meeting  on  13-14  December  2005,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Rotarix on 14 December 2005.  
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 21 February 2006. 
1/1 
©EMEA 2006 
 
 
 
 
